Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Omega Pharma Ltd., 1st Floor, 32 Vauxhall Bridge Road, LONDON, SW1V 2SA, United Kingdom
NiQuitin 7 mg transdermal patches.
Pharmaceutical Form |
---|
Transdermal patch. Each patch is rectangular and is comprised of an outer matt pinkish tan-coloured layer, a middle silver layer and an outer clear layer which is removed prior to use. |
Each 7 cm² transdermal patch contains 36 mg nicotine, equivalent to 5.1 mg/cm² of nicotine and delivering 7 mg over 24 hours.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Nicotine |
Nicotine, the primary alkaloid in tobacco products and a naturally occurring autonomous substance, is a nicotine receptor agonist in the peripheral and central nervous systems and has pronounced CNS and cardiovascular effects. |
List of Excipients |
---|
Drug Reservoir: Ethylene Vinyl Acetate Copolymer Occlusive Backing: Polyethylene/Aluminium/Polyethylene Terephthalate/Ethylene vinyl acetate Rate Controlling Membrane: Polyethylene Film Contact Adhesive and Protective Layer: Polyisobutylene Adhesive Laminate Printing Ink: FGN-7214 NT20 Brown 465 (Ink) |
7 or 14 patches in a carton. Each patch is contained in a laminate sachet.
Omega Pharma Ltd., 1st Floor, 32 Vauxhall Bridge Road, LONDON, SW1V 2SA, United Kingdom
PL 02855/0254
22/04/2009
Drug | Countries | |
---|---|---|
NIQUITIN | Austria, Brazil, Estonia, Spain, France, Ireland, Lithuania, Mexico, Netherlands, Poland, Tunisia, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.